Tanja Grandinetti1, Luc Biedermann2, Christian Bussmann3, Alex Straumann2,4, Petr Hruz5. 1. Department of Gastroenterology and Hepatology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. 2. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. 3. Institute of Pathology Viollier, Basel, Switzerland. 4. Swiss EoE Clinic, Division of Gastroenterology, University Hospital Zurich, Zurich, Switzerland. 5. Department of Gastroenterology and Hepatology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. petr.hruz@usb.ch.
Abstract
BACKGROUND: Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition of the gastrointestinal tract. Little is known about its natural history and treatment outcomes. The aims of our analysis were to describe clinical presentation, response to current medical treatments, and to evaluate the response of refractory EGE to anti-integrin therapy. METHODS: Patients with confirmed diagnosis of EGE fulfilling the diagnostic criteria: (1) the presence of gastrointestinal symptoms, (2) dense eosinophilic infiltration of the gastrointestinal mucosa, and (3) exclusion of other conditions leading to gastrointestinal eosinophilia were included in this analysis. In patients non-responding to corticosteroids and/or anti-TNF treatment the integrin blocker vedolizumab was used. RESULTS: EGE patients (n = 22) were predominantly female (63%) with a median age at diagnosis of 41.5 years. The most frequent symptoms were abdominal pain (100%), diarrhea (59%), nausea/vomiting (36%), and bloating (27%). No pathognomonic endoscopic alterations were found. Eosinophilic infiltration was observed in the majority of patients in more than one segment. Patients were treated with systemic steroids, topical, and enteral release steroids in 21/22 (95%) patients, proton pump inhibitors in 7/22 (32%), TNFα inhibitors in 3/22 (14%), and vedolizumab in 4/22 (18%) patients. In 3/4 of steroid-refractory patients vedolizumab induced a clinical and histological improvement. CONCLUSIONS: The combination of highly variable clinical presentation, subtle endoscopic abnormalities, and involvement of several GI segments undermines the difficulty to diagnose EGE and the need for structured biopsy sampling. Corticosteroids were efficient in the majority of patients to induce remission. Response to the integrin blocker vedolizumab suggests further assessment in refractory cases.
BACKGROUND:Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition of the gastrointestinal tract. Little is known about its natural history and treatment outcomes. The aims of our analysis were to describe clinical presentation, response to current medical treatments, and to evaluate the response of refractory EGE to anti-integrin therapy. METHODS:Patients with confirmed diagnosis of EGE fulfilling the diagnostic criteria: (1) the presence of gastrointestinal symptoms, (2) dense eosinophilic infiltration of the gastrointestinal mucosa, and (3) exclusion of other conditions leading to gastrointestinal eosinophilia were included in this analysis. In patients non-responding to corticosteroids and/or anti-TNF treatment the integrin blocker vedolizumab was used. RESULTS: EGE patients (n = 22) were predominantly female (63%) with a median age at diagnosis of 41.5 years. The most frequent symptoms were abdominal pain (100%), diarrhea (59%), nausea/vomiting (36%), and bloating (27%). No pathognomonic endoscopic alterations were found. Eosinophilic infiltration was observed in the majority of patients in more than one segment. Patients were treated with systemic steroids, topical, and enteral release steroids in 21/22 (95%) patients, proton pump inhibitors in 7/22 (32%), TNFα inhibitors in 3/22 (14%), and vedolizumab in 4/22 (18%) patients. In 3/4 of steroid-refractory patientsvedolizumab induced a clinical and histological improvement. CONCLUSIONS: The combination of highly variable clinical presentation, subtle endoscopic abnormalities, and involvement of several GI segments undermines the difficulty to diagnose EGE and the need for structured biopsy sampling. Corticosteroids were efficient in the majority of patients to induce remission. Response to the integrin blocker vedolizumab suggests further assessment in refractory cases.
Authors: Thomas Greuter; Christian Bussmann; Ekaterina Safroneeva; Alain M Schoepfer; Luc Biedermann; Stephan R Vavricka; Alex Straumann Journal: Am J Gastroenterol Date: 2017-07-18 Impact factor: 10.864
Authors: E Redondo-Cerezo; M J Cabello; Y González; M Gómez; M García-Montero; J de Teresa Journal: Scand J Gastroenterol Date: 2001-12 Impact factor: 2.423
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Robert D Pesek; Craig C Reed; Margaret H Collins; Amanda B Muir; Patricia C Fulkerson; Calies Menard-Katcher; Gary W Falk; Jonathan Kuhl; Adam Z Magier; Faria N Ahmed; Maureen Demarshall; Ankur Gupta; Jonathan Gross; Tokunbo Ashorobi; Christina L Carpenter; Jeffrey P Krischer; Nirmala Gonsalves; Ikuo Hirano; Jonathan M Spergel; Sandeep K Gupta; Glenn T Furuta; Marc E Rothenberg; Evan S Dellon Journal: Dig Dis Sci Date: 2019-11-26 Impact factor: 3.199
Authors: Evan S Dellon; Nirmala Gonsalves; J Pablo Abonia; Jeffrey A Alexander; Nicoleta C Arva; Dan Atkins; Stephen E Attwood; Marcus K H Auth; Dominique D Bailey; Luc Biederman; Carine Blanchard; Peter A Bonis; Paroma Bose; Albert J Bredenoord; Joy W Chang; Mirna Chehade; Margaret H Collins; Carlo Di Lorenzo; Jorge Amil Dias; Ranjan Dohil; Christophe Dupont; Gary W Falk; Cristina T Ferreira; Adam T Fox; Robert M Genta; Thomas Greuter; Sandeep K Gupta; Ikuo Hirano; Girish S Hiremath; Jennifer L Horsley-Silva; Shunji Ishihara; Norihisa Ishimura; Elizabeth T Jensen; Carolina Gutiérrez-Junquera; David A Katzka; Paneez Khoury; Yoshikazu Kinoshita; Kara L Kliewer; Sibylle Koletzko; John Leung; Chris A Liacouras; Alfredo J Lucendo; Lisa J Martin; Emily C McGowan; Calies Menard-Katcher; David C Metz; Talya L Miller; Fouad J Moawad; Amanda B Muir; Vincent A Mukkada; Simon Murch; Quan M Nhu; Ichiro Nomura; Samuel Nurko; Yoshikazu Ohtsuka; Salvatore Oliva; Rok Orel; Alexandra Papadopoulou; Dhyanesh A Patel; Robert D Pesek; Kathryn A Peterson; Hamish Philpott; Philip E Putnam; Joel E Richter; Rachel Rosen; Melanie A Ruffner; Ekaterina Safroneeva; Philipp Schreiner; Alain Schoepfer; Shauna R Schroeder; Neil Shah; Rhonda F Souza; Stuart J Spechler; Jonathan M Spergel; Alex Straumann; Nicholas J Talley; Nikhil Thapar; Yvan Vandenplas; Rajitha D Venkatesh; Mario C Vieira; Ulrike von Arnim; Marjorie M Walker; Joshua B Wechsler; Barry K Wershil; Benjamin L Wright; Yoshiyuki Yamada; Guang-Yu Yang; Noam Zevit; Marc E Rothenberg; Glenn T Furuta; Seema S Aceves Journal: Clin Gastroenterol Hepatol Date: 2022-02-16 Impact factor: 13.576
Authors: Evan S Dellon; Nirmala Gonsalves; Marc E Rothenberg; Ikuo Hirano; Mirna Chehade; Kathryn A Peterson; Gary W Falk; Joseph A Murray; Lauren T Gehman; Alan T Chang; Bhupinder Singh; Henrik S Rasmussen; Robert M Genta Journal: Clin Gastroenterol Hepatol Date: 2021-06-02 Impact factor: 11.382